SCHEMBL13930712

SCHEMBL13930712

COC(=O)c1ccc(N(C[C@@H](C)N2CCC(CC(=O)Nc3ccc(OC)cc3)CC2)S(=O)(=O)Cc2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ POLB P06746 3/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ UBE2M P61081 3/20 0.47
▸ DCUN1D1 Q96GG9 3/20 0.47
▸ MAPT P10636 6/20 0.46
▸ TP53 P04637 1/20 0.46
▸ EPHX2 P34913 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ LMNA P02545 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ GRIN1 Q05586 1/20 0.42
▸ GRIN2B Q13224 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ OPRK1 P41145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13930716 0.94 UBE2M (0.46) SMN1; SMN2POLBRAB9ANPC1UBE2M
SCHEMBL13930692 0.94 UBE2M (0.49) SMN1; SMN2POLBRAB9AUBE2MDCUN1D1
SCHEMBL13930715 0.92 UBE2M (0.46) SMN1; SMN2UBE2MDCUN1D1MAPTTP53
SCHEMBL13930704 0.92 TPSAB1 (0.46) SMN1; SMN2POLBRAB9ANPC1UBE2M
SCHEMBL13930717 0.88 UBE2M (0.45) SMN1; SMN2UBE2MDCUN1D1MAPTEPHX2
SCHEMBL13931078 0.87 SMN1; SMN2 (0.50) SMN1; SMN2POLBRAB9ANPC1MAPT
SCHEMBL13952184 0.86 OPRM1 (0.45) UBE2MDCUN1D1MAPTTP53EPHX2
SCHEMBL13930670 0.85 OPRM1 (0.47) LMNAALDH1A1GRIN1GRIN2B
SCHEMBL13930707 0.85 UBE2M (0.44) SMN1; SMN2UBE2MDCUN1D1EPHX2MEN1
SCHEMBL13930730 0.85 UBE2M (0.51) RAB9ANPC1UBE2MDCUN1D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048291-A1 Novel Piperidine-4-Acetic Acid Derivatives and Their Use EUROSCREEN S.A. (BE) 2009-02-19 — — US disclosed
US-20090048291-A1 Novel Piperidine-4-Acetic Acid Derivatives and Their Use EUROSCREEN S.A. (BE) 2009-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048291-A1 Novel Piperidine-4-Acetic Acid Derivatives and Their Use ALDH1A1, ABAT, ALDH18A1 SMN1; SMN2 2750/4885POLB 1789/4885RAB9A 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback